Echosens North America Names Jon Gingrich as CEO: Global Medical Device Business Executive Leads Strategic US Company Growth Strategy in Liver Disease Assessment

August 27, 2019--WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, today announces the appointment of Jon Gingrich as CEO, Echosens North America, located in Waltham, Massachusetts. With more than 20 years of global medical device and health care sales, marketing and general management experience, Gingrich will lead the development and execution of the U.S. strategy for expanding the utilization of FibroScan technology in the assessment of chronic liver disease. As a member of the broader global leadership team, he will work to implement the Company’s transformation plan and shape the future of Echosens.

Laurent Sandrin, chairman and co-founder of Echosens, welcomes Gingrich, saying, “Jon exemplifies the type of business leadership that will grow our presence in the United States, increase domestic and international adoption of FibroScan technology and drive the overall success of our global enterprise. An accomplished executive with a diverse skillset for leading and scaling business operations, Jon has demonstrated significant success in transforming businesses to sustainable record level growth. He will play a major role in accelerating our position throughout the U.S. healthcare system, and together with Dominique Legros, our newly appointed CEO at the Echosens Group in Paris, France, we will positively impact our growth worldwide.”

Prior to joining Echosens, Gingrich was the chief commercial officer of AxoGen, Inc., a global, publicly traded company that focuses on peripheral nerve repair. Previously, he served as global vice president and general manager, Skeletal Health Solutions, and as Group Global vice president, Marketing, Breast and Skeletal Health Solutions for Hologic, Inc., a global health care and life science developer, manufacturer and supplier of diagnostic, medical imaging and surgical products.

His career also includes 15 years with Boston Scientific, where he held several commercial and international positions of increasing responsibility, including vice president, International Commercialization, Cardiac Rhythm Management, and as general manager, Cardiac Rhythm Management of Japan. During his tenure at Boston Scientific, he also served as: director, International Sales Operations and Training; director, Marketing and Sales, Japan; and in multiple roles for the Endoscopy business unit, including director, Sales Operations, Global Marketing product manager and Executive Territory sales manager.

Gingrich is also credited with successes in sales and marketing at Unilever, N.V., one of the world’s leading consumer goods companies.

Gingrich earned a Bachelor of Science degree in Business Administration with a focus on marketing and management from the University of Richmond. He studied International Management at Oxford Brookes University, United Kingdom, and holds four U.S. and European patents for medical devices.

Gingrich looks forward to molding the Echosens business strategy and execution, adding, “With the looming worldwide epidemic of liver disease, FibroScan products and services take on even greater importance in supporting physicians in their assessment and management of patients with liver diseases. My commitment is to broaden the utilization of these technology solutions, serve an even greater number of providers and payers in both public and private sectors throughout the U.S. healthcare system and make a critical difference in the lives of individuals who face chronic liver disease. Now more than ever, Echosens is positioned for extraordinary growth as it meets these challenges head-on.”

About Echosens

Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. http://www2.echosens.com/AboutFibroScan https://www.echosens.us

Around the web

The investor services labeled recent delays an "untimely distraction" that heightens integration risk after closing the $820M Alliance deal. 

Physicians charge that Zotec Partners is attempting to stifle their legally protected ability to speak about billing concerns, according to court documents.

Feelings of burnout, researchers noted, were especially common among white cardiologists.